Semafore Pharmaceuticals Reports Positive Interim Results F

**Curis helping to treat cancer, neurological degenerative, kidney disorders, CUDC-101. Pathways, hedgehog, EGFR, Her2, Hsp90, Bcr-Abl/Src, CDK, BCL, MEK, VEGF, HDAC.**

Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Clinical Trials News
Reply to topic
Semafore Pharmaceuticals Reports Positive Interim Results F
RSS FEED


Joined: 05 Apr 2006
Posts: 19275
Post Posted: Thu Jun 05, 2008 8:22 am Reply with quote
Semafore Pharmaceuticals Inc. reported interim data from a Phase I study of its lead product candidate, SF1126, a targeted pan-PI3 kinase (PI3K) inhibitor, in patients with advanced solid tumors. SF1126 is the first PI3 kinase inhibitor to be evaluated clinically in both solid tumor and multiple myeloma trials. The data from the solid tumor trial demonstrate that SF1126 is well-tolerated in a twice-weekly I.V.

Read more...
View user's profileSend private message
Semafore Pharmaceuticals Reports Positive Interim Results F
All times are GMT - 7 Hours  
Page 1 of 1  
  
  
Pathway 2 Curis Forum (Hedgehog and beyond) Forum Index » Clinical Trials News
 Reply to topic  
Forum Map
Site Map